Risk factors for the development of pneumonia in patients with immuno-inflammatory rheumatic diseases receiving GIBP in conditions of COVID-19
Y. D. Kurochkina,
M. A. Korolev,
E. A. Letyagina,
N. E. Banshchikova,
A. E. Sizikov,
L. A. Bogoderova,
Y. B. Ubshaeva,
V. O. Omelchenko,
A. A. Akimova,
A. A. Mullagaliev,
O. A. Chumasova,
N. A. Ilyina https://doi.org/10.25789/YMJ.2023.83.15
Abstract
A retrospective analysis of the database of the register of patients with immuno-inflammatory rheumatic diseases receiving treatment with biologic disease-modifying anti-rheumatic drugs in the Novosibirsk region was carried out, which included 318 patients, 94 of whom had indications of pneumonia during the period from 01.04.2020 to 31.12.2020.
There was a statistically significant increase in the risk of developing pneumonia over the age of 60 years and in patients receiving rituximab, while the therapy with TNF-α inhibitors significantly reduced the risk of developing pneumonia.
About the Authors
Y. D. Kurochkina
Research Institute of Clinical and Experimental Lymрhology – Branch of Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences
Russian Federation
Russian Federation
KUROCHKINA Yuliya Dmitrievna – PhD, rheumatology department, research scientist of the laboratory of connective tissue pathology of RICEL
M. A. Korolev
Research Institute of Clinical and Experimental Lymрhology – Branch of Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences
Russian Federation
Russian Federation
KOROLEV Maxim Aleksandrovich – MD, deputy director of RICEL, the leading rheumatologist of Novosibirsk region, head of the laboratory of connective tissue pathology of RICEL
E. A. Letyagina
Research Institute of Clinical and Experimental Lymрhology – Branch of Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences
Russian Federation
Russian Federation
LETYAGINA Elena Alekseevna - PhD, head of rheumatology department of RICEL, senior researcher at laboratory of connective tissue pathology of RICEL
N. E. Banshchikova
Research Institute of Clinical and Experimental Lymрhology – Branch of Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences
Russian Federation
Russian Federation
BANSHCHIKOVA Nadezhda Evgenievna – rheumatologist, junior researcher of the laboratory of connective tissue pathology of RICEL
A. E. Sizikov
Federal State Budgetary Scientific Institution Research Institute of Fundamental and Clinical Immunology
Russian Federation
Russian Federation
SIZIKOV Alexey Eduardovich – PhD, head of rheumatology department of RIFCI
L. A. Bogoderova
State Novosibirsk Regional Clinical Hospital
Russian Federation
Russian Federation
BOGODEROVA Larisa Aleksandrovna – PhD, head of rheumatology department
Y. B. Ubshaeva
Research Institute of Clinical and Experimental Lymрhology – Branch of Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences
Russian Federation
Russian Federation
UBSHAEVA Yuliya Borisovna – PhD, rheumatology, research scientist at laboratory of connective tissue pathology of RICEL
V. O. Omelchenko
Research Institute of Clinical and Experimental Lymрhology – Branch of Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences
Russian Federation
Russian Federation
OMELCHENKO Vitaliy Olegovich – PhD, rheumatologist, research scientist at laboratory of connective tissue pathology of RICEL
A. A. Akimova
Research Institute of Clinical and Experimental Lymрhology – Branch of Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences
Russian Federation
Russian Federation
AKIMOVA Anna Aleksandrovna – rheumatologist, junior researcher at laboratory of connective tissue pathology of RICEL
A. A. Mullagaliev
Research Institute of Clinical and Experimental Lymрhology – Branch of Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences
Russian Federation
Russian Federation
MULLAGALIEV Arsen Arsenovich – junior researcher of the laboratory at pharmacological modeling and screening of bioactive molecules of RICEL
O. A. Chumasova
Federal State Budgetary Scientific Institution Research Institute of Fundamental and Clinical Immunology
Russian Federation
Russian Federation
CHUMASOVA Oxana Aleksandrovna – PhD, rheumatologist department of RIFCI
N. A. Ilyina
Federal State Budgetary Scientific Institution Research Institute of Fundamental and Clinical Immunology
Russian Federation
Russian Federation
LYINA Nadezda Aleksandrovna – rheumatologist department of RIFCI
References
1. doi: 10.26442/00403660.2022.05.201502 Immune-inflammatory rheumatic diseases and COVID-19: analysis of clinical outcomes according to the data of the register of patients of the Novosibirsk region receiving therapy with genetically engineered biological drugs /Korolev M.A. [et al] // Ter. Arkh. 2022. Vol. 94. No. 5. P. 636–641.
2. https://doi.org/10.47360/1995-4484-2021-239-254 Coronavirus Disease 2019 (COVID-19) and Immune-mediated Rheumatic Diseases. Recommendations of the Association of Rheumatologists of Russia / Nasonov E.L [et al.]// Rheumatol. Sci. Pract. 2021. Vol. 59. No 3. P. 239–254.
3. doi: 10.47360/1995-4484-2022-1 Nasonov E.L., Ananyeva L.P., Avdeev S.N. Interstitial lung disease in rheumatoid arthritis: A multidisciplinary problem in rheumatology and pulmonology // Ibid. 2022. Vol. 60. No. 6. P. 517– 534.
4. https://doi.org/10.47360/1995-4484-2021-384-393 Nasonov E.L., Avdeeva A.S. B cell depletion in immune-mediated rheumatic diseases and coronavirus disease 2019 (COVID-19) // Ibid. 2021. Vol. 59. Vol. 4. P. 384–393.
5. https://doi.org/10.47360/1995-4484-2021-666-675 Nasonov E.L. et al. Course and outcomes of COVID-19 in patients with immunoinflammatory rheumatic diseases: Preliminary data from the NIIR/APP-COVID-19 registry and literature review // Ibid. 2021b. Vol. 59. Vol. 6. P. 666–675.
6. Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases / Boyarsky B.J. [et al.] //Ann. Rheum. Dis. 2021. Vol. 80. No. 8. P. 1098–1099. https://doi.org/10.1136/annrheumdis-2021-220289
7. Characteristics and evolution of 38 patients with rheumatic diseases and COVID-19 under DMARD therapy / Galarza-Delgado D.Á [et al.] // Clin. Rheumatol. 2021. Vol. 40. № 3. P. 1197–1199. Available from: http://link.springer.com/10.1007/s10067-020-05510-9
8. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry/ Gianfrancesco M [et al.]// Ann. Rheum. Dis. 2020. Vol. 79. No. 7. P. 859–866. https://doi.org/10.1136/annrheumdis-2020-217871
9. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study/ Zhou F. [et al.] // Lancet. 2020. Vol. 395. No. 10229. P. 1054–1062. DOI: https://doi.org/10.1016/S0140-6736(20)30566-3
10. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies / Monti S [et al.]// Ann. Rheum. Dis. 2020. Vol. 79. No. 5. P. 667– 668. https://doi.org/10.1136/annrheumdis-2020-217424
11. Coronavirus disease 2019 (COVID-19) in patients with systemic autoimmune diseases or vasculitis: radiologic presentation / Eslambolchi A [et al.] // J. Thromb. Thrombolysis. 2021. Vol. 51. No. 2. P. 339–348. Available from: https://link.springer.com/10.1007/s11239-020-02289-z
12. COVID-19 in Patients With Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and Disease-Modifying Antirheumatic Drugs on Clinical Outcomes / Haberman R.H. [et al.] // Arthritis Rheumatol. 2020. Vol. 72. No. 12. P. 1981–1989. https://doi.org/10.1002/art.41456
13. EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update / Landewé R.B.M [et al.] // Ann. Rheum. Dis. 2022. С. annrheumdis-2021-222006. https://doi.org/10.1136/annrheumdis-2021-222006
14. High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study/ Loarce-Martos J [et al.]// Rheumatol. Int. 2020. Vol. 40. No. 12. P. 2015–2021. Available from: http://link.springer.com/10.1007/s00296-020-04699-x
15. Longterm Safety of Patients Receiving Rituximab in Rheumatoid Arthritis Clinical Trials / VOLLENHOVEN R.F. van [et al.]// J. Rheumatol. 2010. Vol. 37. No. 3. P. 558–567. https://doi.org/10.3899/jrheum.090856
16. Moore J.B., June C.H. Cytokine release syndrome in severe COVID-19 // Science (80-). 2020. Vol. 368. No. 6490. P. 473–474. https://doi.org/10.1126/science.abb8925
17. Murakami M., Kamimura D., Hirano T. Pleiotropy and Specificity: Insights from the Interleukin 6 Family of Cytokines // Immunity. 2019. Vol. 50. No. 4. P. 812–831. Available from: https://linkinghub.elsevier.com/retrieve/pii/S107476131930144X
18. Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients /Zhou Y. [et al.] // Natl. Sci. Rev. 2020b. Vol. 7. No. 6. P. 998–1002. doi: 10.1093/nsr/nwaa041
19. Pathological evidence for residual SARSCoV-2 in pulmonary tissues of a ready-for-discharge patient /Yao X.-H. [et al.] // Cell Res. 2020. Vol. 30. No. 6. P. 541–543. DOI: 10.1038/s41422-020-0318-5
20. Pathological findings of COVID-19 associated with acute respiratory distress syndrome/ Xu Z. [et al.] // Lancet Respir. Med. 2020. Vol. 8. No. 4. P. 420–422. DOI: 10.1016/S2213-2600(20)30076-X
21. Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld) for COVID-19 among 1112 severely immunocompromised patients/ Y. Nguyen [et al.] // Clinical Microbiology and Infection.2022. Vol. 28. P. 1654.e1e1654.e4. https://doi.org/10.1016/j.cmi.2022.07.015
22. SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response/ Bonelli M.M [et al.] // Ann. Rheum. Dis. 2021. Vol. 80. No. 10. P. 1355–1356. https://doi.org/10.1136/annrheumdis-2021-220408
23.
Review
For citations:
Kurochkina Y.D., Korolev M.A., Letyagina E.A., Banshchikova N.E., Sizikov A.E., Bogoderova L.A., Ubshaeva Y.B., Omelchenko V.O., Akimova A.A., Mullagaliev A.A., Chumasova O.A., Ilyina N.A. Risk factors for the development of pneumonia in patients with immuno-inflammatory rheumatic diseases receiving GIBP in conditions of COVID-19. Yakut Medical Journal. 2023;(3):61-64. https://doi.org/10.25789/YMJ.2023.83.15
Views:
18
Email this article 